****UPDATE: REVIVE THERAPEUTIC FUNDAMENTAL DD...****
The Shocking Truth About Bucillamine is already being manufactured/produced, all that needs to happen is it get approved for COVID-19 treatment. Bucillamine know no toxicity related to drug. In light of this I honestly believe three to six months tops until it's approved and on its way to market. It is important that you understand, you be aware of all the changes that company making. Therefore, I urge you to see it once June Investor presentation. They have their highest market cap comparison at 3.7 billion that equal to $15 dollars per share. In my humble opinion I will tell you this is only the beginning! There will be a lot more exciting NEWS coming. I'm looking forward to see they announce sponsor/partnership, funding...NEAR TERM CATALYST I list at the end of my DD page. Enjoy to read my DD.
CYDY O/S 564 Million 3 times higher than RVVTF (both) stock list on OCT. CYDY move from .35 to $10.00 on phase2 trial. It only makes sense to see us run past that ten dollar mark.
A Study of N-acetylcysteine in Patients With COVID-19 Infection. The study researchers think that a medication called N-acetylcysteine can help fight the COVID-19 virus by boosting a type of cell in your immune system that attacks infections. View link bellow:
Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC. (N-Acetyl Cysteine (Nac) It's no wonder the FDA gave it the fast track go ahead into phase 3.
A must watch video: Analyst sees 'substantial upside potential' as key assets move towards clinic
NEAR TERM CATALYST :
1 * Initiate Phase 3 clinical study of Bucillamine in the treatment of COVID-19 in the U.S
2. Asia updates on trials for Covid-19 Bucillamine
3. Canadian updates on Covid-19 Bucillamine
4. Q2 Submit IND for Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatitis
5 * Q2/3 Pre-IND meeting with FDA for Bucillamine in various infectious diseases (undisclosed)
6 * Q3 Initiate Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatitis
7. Q3 Pre-IND meeting with FDA for Psilocybin (undisclosed indications)
8 * Q3/4 Results from Phase 2 clinical study of Bucillamine in the treatment of COVID-19
9 * Q4 Results from Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatitis
10 * Q4 Submit FDA IND for Phase 2 clinical study of Bucillamine (undisclosed indication)
11 * Patent News Updates
12 * Sponsor/Partnership for Trials
13 * Funding
14 * Potential buyout could be Billions for a biotech company
16. Manufacturing deal Atwill Medical Solutions CEO is on the Revive board just signed a deal with VXRT This could lead to potential partnership/deals in the future. IMHO:))
Revive has an exclusive license from South Carolina Research Foundation for its intellectual property for the use of CBD. (U.S. patent No. 8242178). Also, the FDA has granted to Revive orphan drug designation for CBD in the treatment of AIH.
News 
Market Data 
Discover 
AI
